Want to see QDEL full AI Analyst Report?
QDEL Stock Chart & Stats
$16.05
$0.78(4.86%)
At close: 4:00 PM EDT
$16.05
$0.78(4.86%)
Day’s Range― - ―
52-Week Range$9.92 - $35.58
Previous Close$16.9
Volume1.06M
Average Volume (3M)1.47M
Market Cap
$1.02B
Enterprise Value$3.89K
Total Cash (Recent Filing)$123.40M
Total Debt (Recent Filing)$3.08B
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Nov 04, 2026EPS Estimate
0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.44
Shares Outstanding68,575,424
10 Day Avg. Volume1,045,833
30 Day Avg. Volume1,465,730
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.03
Price to Sales (P/S)0.73
P/FCF Ratio-23.93
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.00Price Target Upside-6.54% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)0.78
Revenue Forecast (FY)$2.55B
Bulls Say, Bears Say
Bulls Say
Diversified Ex-China Franchise GrowthBroad growth across core laboratory, transfusion and point-of-care franchises indicates resilient underlying demand and reduces reliance on China. Continued regional expansion can support recurring consumables revenue over the next several quarters.
EBITDA And Operating Discipline ImprovingStrong EBITDA growth and margin expansion, alongside controlled SG&A and R&D growth, suggest productivity actions are improving operating leverage. If sustained, this can strengthen profitability despite modest revenue growth.
Lex/Neulixa Commercialization PlatformThe Lex acquisition adds a respiratory testing opportunity to QuidelOrtho’s existing portfolio. Progress in manufacturing and commercial readiness could expand the installed base and generate recurring assay utilization during future respiratory seasons.
Bears Say
Deep Losses And Negative Cash GenerationLarge losses and cash consumption weaken internal funding capacity and may constrain investment or debt reduction. The deterioration is particularly concerning because recurring consumables revenue has not yet translated into sustainable company-wide cash generation.
Persistent China Pricing UncertaintyBroader pricing pilots and inventory reductions create a structural risk to China demand, pricing and margins rather than a one-quarter disruption. Persistent uncertainty could delay purchasing and pressure the company’s international growth profile.
Elevated Leverage And Margin PressureHigh leverage increases the importance of cash conversion and limits financial flexibility while gross-margin pressure signals unfavorable mix and pricing effects. Together, these factors could slow deleveraging and prolong earnings recovery.
QuidelOrtho News
QDEL FAQ
What was Quidelortho Corporation’s price range in the past 12 months?
Quidelortho Corporation lowest stock price was $9.92 and its highest was $35.58 in the past 12 months.
What is Quidelortho Corporation’s market cap?
Quidelortho Corporation’s market cap is $1.02B.
When is Quidelortho Corporation’s upcoming earnings report date?
Quidelortho Corporation’s upcoming earnings report date is Nov 04, 2026 which is in 73 days.
How were Quidelortho Corporation’s earnings last quarter?
Quidelortho Corporation released its earnings results on Aug 06, 2026. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of -$0.049 by $0.179.
Is Quidelortho Corporation overvalued?
According to Wall Street analysts Quidelortho Corporation’s price is currently Overvalued.
Does Quidelortho Corporation pay dividends?
Quidelortho Corporation does not currently pay dividends.
What is Quidelortho Corporation’s EPS estimate?
Quidelortho Corporation’s EPS estimate is 0.21.
How many shares outstanding does Quidelortho Corporation have?
Quidelortho Corporation has 68,575,424 shares outstanding.
What happened to Quidelortho Corporation’s price movement after its last earnings report?
Quidelortho Corporation reported an EPS of $0.13 in its last earnings report, beating expectations of -$0.049. Following the earnings report the stock price went down -24.724%.
Which hedge fund is a major shareholder of Quidelortho Corporation?
Currently, no hedge funds are holding shares in QDEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
QuidelOrtho Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$15.00 (-6.54% Downside)
$15.00 (-6.54% Downside)
Blogger Sentiment
Neutral
QDEL Sentiment 60%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 439.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.04%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-10.41%
Trailing 12-Months
Company Description
Quidelortho Corporation
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
QDEL Company Deck
QDEL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed a mixed picture: solid underlying operational performance outside China (mid-single-digit growth ex-China, strong regional results, 21% YoY adjusted EBITDA growth, and margin expansion) and tangible progress on the Lex/Neulixa commercialization. Offsetting these positives were significant near-term headwinds — a 23% revenue decline in China driven by IVD pricing uncertainty, a softer respiratory season, negative operating and free cash flow in the quarter, withdrawal of free-cash-flow guidance, and elevated leverage (4.3x). Management emphasized disciplined cost actions, cash-conversion priorities, and mitigation plans, but the combination of China uncertainty and weak respiratory demand creates meaningful short-term risk even as core franchises remain resilient.View all QDEL earnings summariesQDEL Stock 12 Month Forecast
Average Price Target
$15.00
▼(-6.54% Downside)
Technical Analysis
Ownership Overview
0.89% Insiders
40.99% Mutual Funds
18.47% Other Institutional Investors
5.68% Public Companies and
Individual Investors